As global markets grapple with volatility and shifts in investor sentiment, the Asian market continues to present unique ...
Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...
Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.
2026 could be a big year for this company.
Among the 22 companies under coverage, the analysts highlight six stocks - Ionis, Beam, Taysha, Sarepta, Spyre, and RAPT, as their strongest ideas for 2026, reflecting robust pipelines, near-term data ...
Investor's Business Daily on MSN
Dow Jones leader Amgen leads these biotech stocks heading into Q4 earnings season
Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.
The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...
UBS gave its highest conviction calls for 2026, laying out its top stock picks across sectors. The bank is bullish on a wide variety of companies spanning several high-growth sectors. A few of its top ...
On December 24, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that healthcare has become the top-performing sector over the last 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results